Key Quantitative Figures (Consolidated for Q2 FY27)

  • Revenue from Operations: ₹3,090.70 million (Q2 FY27) vs. ₹2,470.58 million (Q2 FY26)
  • Total Income: ₹3,192.40 million (Q2 FY27)
  • Profit Before Tax (PBT): ₹954.80 million (Q2 FY27)
  • Profit After Tax (PAT): ₹695.72 million (Q2 FY27)
  • Earnings Per Share (EPS): ₹6.65 (Basic & Diluted, not annualized for the quarter)
  • Paid-up Equity Share Capital: ₹104.62 million (Face value of ₹1 each)

Key Quantitative Figures (Standalone for Q2 FY27)

  • Revenue from Operations: ₹3,123.14 million (Q2 FY27)
  • Profit After Tax (PAT): ₹757.14 million (Q2 FY27)
  • Earnings Per Share (EPS): ₹7.24 (Basic & Diluted, not annualized for the quarter)

Dates of Action

  • Board Meeting Date: October 27, 2026 (commenced at 3:30 PM, concluded at 4:45 PM)
  • Bonus Share Record Date: Fixed as Wednesday, November 04, 2026
  • Financial Period: Results are for the quarter and half year ended September 30, 2026.

Parties Involved

  • Subsidiaries: Concord Lifegen Ltd. (Wholly owned), Celliimune Biotech Pvt. Ltd. (Wholly owned, acquired April 02, 2026), Stellon Biotech Inc. (Subsidiary)
  • Joint Venture: Concord Biotech Japan K.K.
  • Statutory Auditors: M/s. BSR & Co. LLP
  • Compliance Officer: Paritosh Trivedi
  • Chairman & Managing Director: Sudhir Vaid (DIN: 00055967)

Purpose and Rationale

The Board meeting was held to review and approve the financial performance for the second quarter and to decide on corporate actions, including the bonus issue and committee reconstitution, as part of regular governance and compliance.

Capital Structure Impact

The bonus issue is in the ratio of 1:1. The company had previously increased its Authorised Share Capital from ₹11 crore to ₹22 crore (subject to shareholder approval) to facilitate this issuance. The record date (Nov 4, 2026) confirms the timeline for the capital change.

Financial and Operational Impact (as disclosed)

The financial results detail the company's profitability and comprehensive income. An exceptional item of ₹3.275 million related to the statutory impact of new labour codes was recognized in the previous fiscal year (FY26).

Forward-Looking Guidance

No explicit forward-looking guidance or management commentary is provided in this specific disclosure.

Committee Reconstitution

The Board reconstituted its key committees. The new compositions are:

  • Audit Committee: Mr. Arvind Agarwal (Chairman), Mr. Jayaram Easwaran, Mr. Ravi Kapoor
  • Nomination & Remuneration Committee: Mr. Mandayam Chakravarthy Sriraman (Chairman), Mr. Arvind Agarwal, Mrs. Ekta Gupta
  • Risk Management Committee: Mr. Ankur Vaid (Chairman), Mr. Ravi Kapoor, Mr. Mandayam Chakravarthy Sriraman
  • CSR Committee: Mr. Ankur Vaid (Chairman), Mr. Rajiv Agarwal, Mrs. Ekta Gupta

Auditor's Limited Review

BSR & Co. LLP issued a limited review report for both standalone and consolidated results. Their review did not cover the interim financials of two subsidiaries and one joint venture, which were deemed not material to the group. The conclusion was not modified due to this scope limitation.